Tetravalent multispecific ADC (Aarvik Therapeutics)

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameTetravalent multispecific ADC (Aarvik Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 8Anti-HER2Anti-Programmed death-ligand 1 +[4] 
TargetsTumor necrosis factor receptor superfamily member 8Receptor protein-tyrosine kinase erbB-2Programmed death-ligand 1 +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAarvik Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAarvik Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A